Stock Market Reviews

Read and share opinions on TEVA (Teva Pharmaceutical Industries Limited) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in th

Latest News

• What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)?
  Dec 30, 2025
• This International Pharma Stock Just Hit 5-Year Highs
  Dec 26, 2025
• S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
  Dec 24, 2025
• Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
  Dec 19, 2025
• BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight
  Dec 17, 2025
• 3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today
  Dec 17, 2025
• Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
  Dec 14, 2025
• Will Teva’s (TEVA) Extended Sustainability-Linked Credit Line Reshape Its Balance Sheet and Risk Narrative?
  Dec 13, 2025
• Has Teva’s 80% Surge in 2024 Already Priced In Its Turnaround Potential?
  Dec 13, 2025
• Teva Releases Q4 2025 Aide Memoire
  Dec 12, 2025
• Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
  Dec 12, 2025
• Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
  Dec 11, 2025

TEVA News

• Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
  Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026.
  Dec 30, 2025
• What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)?
  Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable healthcare stocks to buy now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on December 24 that S&P Global Ratings upgraded the company’s long-term issuer credit rating to ‘BB+’ from ‘BB’ with a stable outlook. Moody’s Ratings Agency also affirmed the company’s B1a rating, revising its outlook […]
  Dec 30, 2025
• This International Pharma Stock Just Hit 5-Year Highs
  Teva Pharmaceutical (TEVA) is trading at new 5-year highs. Shares are up more than 40% over the past year. The stock has strong technical momentum, maintaining a 100% “Buy” opinion from Barchart. TEVA offers international diversification and is favored by both Wall Street and individual investors. Today’s Featured Stock Valued...
  Dec 26, 2025
• S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
  The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stableS&P upgraded Teva to BB+ from BB, with a stable outlook TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, with a s
  Dec 24, 2025
• J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play
  J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum.
  Dec 22, 2025
• Teva Pharmaceutical Industries' (NYSE:TEVA) investors will be pleased with their impressive 228% return over the last three years
  The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
  Dec 21, 2025
• Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
  According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Ind
  Dec 19, 2025
• Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
  Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
  Dec 18, 2025
• Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
  License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports Sagimet’s fixed-dose combination (FDC) program currently in clinical developmentSagimet’s Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025Sagimet anticipates selecting one of the innovative form
  Dec 17, 2025
• 3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today
  Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.
  Dec 17, 2025
• BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight
  We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Teva Pharmaceuticals Industries Limited is one of the most undervalued stocks on our list. TheFly reported on December 9 that Bank of America Securities analyst Jason Gerberry reaffirmed a Buy rating on TEVA and raised his price target to $32.00, reflecting […]
  Dec 17, 2025
• S&P 500 Stocks: These 2 Lagging Retailers Become Leaders In December
  Lululemon shares are up more than 20% over the past month, the 11th best performance in the S&P 500.
  Dec 17, 2025
• FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?
  Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda.
  Dec 16, 2025
• Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
  Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.
  Dec 14, 2025
• Has Teva’s 80% Surge in 2024 Already Priced In Its Turnaround Potential?
  Wondering if Teva Pharmaceutical Industries is still a value play after its huge run, or if you have already missed the boat? This breakdown is designed to cut through the noise and focus on what the current price really implies. The stock has climbed 4.7% over the last week, 15.3% over the past month, and a striking 39.9% year to date, capping off an 80.5% gain over the last year and more than tripling over three years. That surge has coincided with renewed optimism around Teva's turnaround...
  Dec 13, 2025
• Will Teva’s (TEVA) Extended Sustainability-Linked Credit Line Reshape Its Balance Sheet and Risk Narrative?
  Teva Pharmaceutical Industries recently secured lender consent to extend the maturity of its senior unsecured sustainability-linked revolving credit facility to April 29, 2028, while easing certain leverage and interest coverage covenants and providing flexibility tied to potential future investment-grade status. This extension, alongside progress in higher-margin branded and biosimilar products and growing institutional interest, underscores Teva’s efforts to strengthen its balance sheet...
  Dec 13, 2025
• Teva Releases Q4 2025 Aide Memoire
  TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8
  Dec 12, 2025
• Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
  TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webc
  Dec 12, 2025
• Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
  Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning. He has been piling into Natera (NASDAQ:NTRA), Insmed (NASDAQ:INSM), and Teva Pharmaceuticals (NYSE:TEVA) as of late, and we’ll get into why. Druckenmiller first gained fame by managing George Soros’s Quantum Fund, where he orchestrated ... Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
  Dec 11, 2025
• TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia
  Teva files an NDA seeking FDA approval for its once-monthly olanzapine LAI for the treatment of adults with schizophrenia.
  Dec 10, 2025
• Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
  Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
  Dec 9, 2025
• Looking at the Narrative for Teva After Evolving Price Targets and Austedo Outlook
  Teva Pharmaceutical Industries just saw its fair value estimate nudged higher from about $27.90 to roughly $28.60, as analysts grow more confident in the company’s turnaround story. The discount rate remains steady near 8.52%, while long term revenue growth expectations have been trimmed from around 2.51% to about 2.12%. This reflects a more measured view of the top line despite stronger earnings visibility. Stay tuned to see how you can monitor these evolving targets and keep up with the...
  Dec 9, 2025
• Teva Pharmaceutical Industries (NYSE:TEVA): Reassessing Valuation After a Strong Multi‑Month Share Price Rebound
  Teva Pharmaceutical Industries (NYSE:TEVA) has quietly turned into one of this year’s stronger pharma rebound stories, with the stock climbing about 18% over the past month and roughly 45% in the past 3 months. See our latest analysis for Teva Pharmaceutical Industries. At around $28.33 per share, Teva’s strong 30 day and year to date share price returns, alongside a powerful three year total shareholder return, suggest momentum is building as investors reassess both its earnings trajectory...
  Dec 9, 2025
• Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
  Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
  Dec 9, 2025
• Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
  Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1Teva is committed to advancing this innovative treatment option and further build on its differentiated LAI franchise PARSIPPANY, N.J. and TEL AVIV, Isr
  Dec 9, 2025
• Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
  MONTPELLIER, France, December 09, 2025--Regulatory News: Medincell (Paris:MEDCL):
  Dec 9, 2025
• Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing
  Glenview Capital Management added to its massive position in Teva Pharmaceuticals stock.
  Dec 9, 2025
• Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?
  J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.
  Dec 8, 2025
• 3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
  Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
  Dec 8, 2025
• Is Deckers Outdoor Stock Underperforming the S&P 500?
  Deckers Outdoor has significantly underperformed the S&P 500 over the past year, yet analysts remain cautiously optimistic about the stock’s prospects.
  Dec 8, 2025
• Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
  Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing after its COVID revenue collapse while Teva is accelerating through an innovation-led turnaround that has delivered 11 consecutive quarters of growth. One Declining, One Accelerating Pfizer posted Q3 revenue of ... Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
  Dec 6, 2025
• Can Galafold Continue to Drive Amicus' Top Line in 2026?
  FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026.
  Dec 5, 2025
• Should We Be Cautious About Teva Pharmaceutical Industries Limited's (NYSE:TEVA) ROE Of 9.1%?
  Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
  Dec 5, 2025
• Israel Has Been Mired In Controversy During Its War With Hamas. Big Tech Investment Tells A Different Story.
  Israel's stock market has outpaced U.S. markets since Oct. 7, 2023, with U.S.-traded leaders like Teva, Elbit Systems and Tower Semiconductor showing big gains.
  Dec 4, 2025
• Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
  Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
  Dec 2, 2025
• ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America
  ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy. Edward Jo
  Dec 1, 2025
• With 72% ownership in Teva Pharmaceutical Industries Limited (NYSE:TEVA), institutional investors have a lot riding on the business
  Key Insights Significantly high institutional ownership implies Teva Pharmaceutical Industries' stock price is...
  Nov 30, 2025
• Is Teva a Bargain After 27% Surge and Cost-Cutting Headlines?
  Wondering if Teva Pharmaceutical Industries is now a bargain or if you might be late to the party? You're not alone. Investors are searching for value in a market where expectations are shifting fast. Teva's stock has climbed 2.3% over the past week and 27.4% in the last month. This adds up to a 50.8% gain over the past year and a 184.9% return in three years. Recent headlines have put Teva in the spotlight due to its progress with cost-cutting initiatives and a stronger balance sheet, which...
  Nov 26, 2025
• European Biosimilar Approvals Could Be a Game Changer for Teva Pharmaceutical Industries (TEVA)
  In recent days, Teva Pharmaceutical Industries received European Commission marketing authorizations for its denosumab biosimilars, PONLIMSI and DEGEVMA, which target bone health treatments across Europe. This regulatory milestone aligns with Teva’s Pivot to Growth strategy and enables the company to expand its biosimilars portfolio in key European markets. We'll now explore how these European biosimilar approvals may influence Teva's future growth trajectory and overall investment...
  Nov 26, 2025
• Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied
  Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the Inflation Reduction Act.
  Nov 26, 2025
• Why Analysts See Teva’s Story Shifting With New Approvals and Rising Price Targets
  Teva Pharmaceutical Industries stock has drawn renewed attention after consensus analyst price targets edged higher, rising from $27.45 to $27.90 per share. This subtle adjustment reflects a blend of cautious optimism, influenced by both regulatory developments and performance expectations. As analysts weigh potential growth opportunities alongside persistent industry risks, readers will want to follow closely to stay informed on the evolving narrative shaping Teva’s outlook. Analyst Price...
  Nov 25, 2025
• Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
  Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments across Europe These approvals mark another significant milestone in Teva’s strong biosimilars portfolio, in line with Teva's Pivot to Growth StrategyThe approvals underscore Teva’s commitment to broadening access to biosimilars TEL AVIV, Israel, No
  Nov 25, 2025
• What Are Wall Street Analysts' Target Price for Deckers Outdoor Stock?
  Despite Deckers Outdoor’s significant underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
  Nov 25, 2025
• This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.
  Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing. He’s now piling into Natera (NASDAQ:NTRA), Insmed (NASDAQ:INSM), and Teva Pharmaceutical (NYSE:TEVA). They’re worth looking into, as Druckenmiller has an exceptional record. In 1977, Druckenmiller started his financial career as an oil ... This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.
  Nov 24, 2025
• Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
  TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows: 8th Annual Evercore Healthcare ConferenceWednesday, December 3, 2025, at 8:20 A.M. Eastern Time (ET)Piper Sandler 37th Annual Healthcare ConferenceWednesday, December 3, 2025, at 11:00 A.M. Eastern Time (ET)C
  Nov 21, 2025
• Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
  Teva Launches Teva Rise Teva Launches Rise - Global Open Innovation Platform First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosyste
  Nov 19, 2025
• Teva seeks startups to help solve global pharmaceutical challenges
  JERUSALEM (Reuters) -Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new ​platform to develop technologies to deal with a host of challenges facing ‌Teva and the global pharmaceuticals industry. Called Teva Rise, the company's open innovation platform aims ‌to accelerate innovations such as AI, digital health, smart manufacturing and biotech, and will connect startups and tech companies with Teva's business units, it said.
  Nov 19, 2025
• Teva (NYSE:TEVA): Exploring Valuation After a 29% One-Month Rally
  Teva Pharmaceutical Industries (NYSE:TEVA) has seen its stock climb nearly 29% over the past month, catching the eye of investors interested in the pharmaceutical sector. Momentum appears steady, and recent performance is prompting fresh discussion around the company's forward outlook. See our latest analysis for Teva Pharmaceutical Industries. Zooming out, Teva’s momentum is not just a short-term story. Its 1-year total shareholder return stands at a robust 47.77%, while the 3-year total...
  Nov 19, 2025
• Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
  Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
  Nov 18, 2025
• Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
  The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio
  Nov 18, 2025
• ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
  ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
  Nov 14, 2025
• Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
  Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
  Nov 13, 2025
• We Like The Quality Of Teva Pharmaceutical Industries' (NYSE:TEVA) Earnings
  Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) announced a healthy earnings result recently, and the market...
  Nov 12, 2025
• Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
  Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
  Nov 10, 2025
• How Recent Developments Are Rewriting the Story for Teva Pharmaceutical Industries
  Teva Pharmaceutical Industries has seen its fair value price target rise from $24.44 to $27.45, reflecting renewed optimism among analysts after the latest quarterly updates. This upward shift comes as revenue growth projections have improved from 2.43% to 2.77%, supported by positive trends in drug pricing and sales volumes. Stay tuned to learn how you can stay ahead of future developments in Teva’s evolving investment story. Analyst Price Targets don't always capture the full story. Head...
  Nov 9, 2025
• Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
  Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
  Nov 7, 2025
• AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
  In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XRMost (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition remained stable or improved Teva is committed to truly understanding and empowering individuals living with TD to help improve their TD and regain th
  Nov 7, 2025
• S&P 500 Futures Dip as Rate and Debt Worries Mount
  The Morning Bull - US Market Morning Update Thursday, Nov, 6 2025 US stock futures are pointing lower ahead of the open, as investors react to news that US household debt has climbed to a fresh all-time high and the 10-year Treasury yield has pushed to its highest level in a month. Signs of persistent borrowing and rising rates are stirring fresh concern about consumer resilience and the cost of credit, which is putting pressure on the broader equity market as investors weigh the trajectory...
  Nov 6, 2025
• Teva (TEVA) Hits Multi-Year High as Q3 Strengthens FY25 Profitability Expectations
  We recently published 10 Big Names Leading Wall Street Gains. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the best-performing stocks on Wednesday. Teva rallied to a new multi-year high on Wednesday after a stellar performance in the third quarter solidified expectations for a profitable full-year 2025. In intra-day trading, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) […]
  Nov 6, 2025
• TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
  Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
  Nov 6, 2025
• Teva Canada Welcomes RAMQ Reimbursement Update Supporting Access to ADHD Treatments
  Teva Canada welcomes the recent announcement from Québec's Ministry of Health regarding changes to the reimbursement framework for extended-release methylphenidate products. Effective December 11, 2025, the Régie de l'assurance maladie du Québec (RAMQ) will apply the "lowest price" method to the molecule category "methylphenidate (hydrochloride) Co. L.A (12 h)."
  Nov 6, 2025
• Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
  Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
  Nov 5, 2025
• Teva Hits Highest Since 2018 as 3Q Revenue Beats Estimates
  Teva Pharmaceutical CEO Richard Francis speaks about 3Q earnings on Bloomberg BusinessWeek with Bloomberg's Katie Greifeld and Emily Graffeo.
  Nov 5, 2025
• Sector Update: Health Care Stocks Higher in Afternoon Trading
  Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the Health
  Nov 5, 2025
• Top Midday Stories: McDonald's Shares Rise After Q3 Same-Store Sales Growth; AMD Q3 Adjusted EPS, Revenue Beat Estimates
  All three major US stock indexes were up in late-morning trading Wednesday, as some big artificial-i
  Nov 5, 2025
• Sector Update: Health Care Stocks Advance Late Afternoon
  Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 0.4% and th
  Nov 5, 2025
• Apple's reported Google deal, Teva & Axon post-earnings moves
  Market Domination host Josh Lipton examines some of Wednesday's trending tickers. Apple (AAPL) is reportedly nearing a deal with Alphabet (GOOG, GOOGL) to overhaul Siri, according to Bloomberg. Teva (TEVA) stock rose after the company reported earnings, while Axon (AXON) stock fell after the company's quarterly results missed estimates. To watch more expert insights and analysis on the latest market action, check out more Market Domination.
  Nov 5, 2025
• Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth ...
  Teva Pharmaceutical Industries Ltd (TEVA) reports its 11th consecutive quarter of growth, driven by innovative products, despite facing challenges in the generics market and cash flow.
  Nov 5, 2025
• Why Teva Pharmaceutical Stock Rocked the Market Today
  The company delivered a convincing pair of beats in its third-quarter earnings report.
  Nov 5, 2025
• Teva Rockets, Reaffirming Its $2.5 Billion View For Austedo After IRA Negotiations
  Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its drug Austedo in the U.S.
  Nov 5, 2025

TEVA Reviews

• MarketMyth

  Dec 30, 2025

  $TEVA This company is building on its extensive portfolio of generic and specialty medications, showcasing a strong commitment to innovation and patient-centric solutions. Recent developments indicate a positive trajectory in addressing market needs, positioning it for growth amidst evolving healthcare landscapes.

  Buy

• GainsOverBrains

  Dec 30, 2025

  $TEVA Pharma hustle strong, watch it bounce back like a champ!

  Buy

• MarketGlitch

  Dec 30, 2025

  $TEVA Facing patent challenges and market pressures feels like a double-edged sword! Can this giant adapt quickly enough to turn the tide, or are they destined for more struggles? The uncertainty is enough to keep anyone awake at night!

  Sell

• CashWraith

  Dec 30, 2025

  $TEVA Amidst mounting pressures in the pharmaceutical industry, this company must find a breakthrough. The challenges are daunting, and the need for innovation is urgent!

  Sell

• PortfolioGremlin

  Dec 30, 2025

  $TEVA Dropping meds like it's hot, stay sharp on this one!

  Buy

• GainsOverBrains

  Dec 30, 2025

  $TEVA Pharma vibes are shaky, tread carefully in this jungle!

  Sell

• DividendDemon

  Dec 29, 2025

  $TEVA This stock is like that kid who keeps borrowing your lunch money; you wonder if it’s ever going to pay you back!

  Sell

• AlphaStriker

  Dec 28, 2025

  $TEVA Pharma giant? More like a sinking ship.

  Sell

• WallStreetWraith

  Dec 28, 2025

  $TEVA Just another giant stumbling through the pharmacy aisle.

  Sell

• VolatilityStrike

  Dec 28, 2025

  $TEVA Facing intense competition, this established pharmaceutical company is working to enhance its portfolio, navigating challenges with strategic adjustments.

  Sell

• BullishShade

  Dec 28, 2025

  $TEVA As a leader in generics and specialty medicines, this company is well-positioned to capitalize on the growing demand for affordable healthcare solutions. Their efforts in research and development could enhance their portfolio and market presence.

  Buy

• FUDCrusher

  Dec 27, 2025

  $TEVA Been around the block, but can they bounce back strong?

  Sell

• VolatileViking

  Dec 27, 2025

  $TEVA Like a superhero with a lab coat, they're fighting the good fight in pharmaceuticals – cape not included!

  Buy

• LiquidityLord

  Dec 27, 2025

  $TEVA Navigating a challenging pharmaceutical landscape, this entity is focusing on operational efficiencies and pipeline development, which could prove crucial in reclaiming its competitive footing in the industry.

  Sell

• TickerTakedown

  Dec 26, 2025

  $TEVA This stock is like the dependable friend who always has a backup plan – there when you need it, just don’t ask for a ride!

  Sell

• TheQuantEdge

  Dec 26, 2025

  $TEVA Caught in a battle of generics and patent expirations, can this pharmaceutical titan turn the tides? The pressure is immense, and the market is unforgiving for those who falter.

  Sell

• MarketGlitch

  Dec 26, 2025

  $TEVA In the cutthroat pharmaceutical landscape, every move feels like a gamble. Can this company navigate the complexities, or is it stuck in a web of litigation and concerns?

  Sell

• ManiaBroker

  Dec 26, 2025

  $TEVA Making medicine like it’s a new recipe in a cooking class; let’s just hope it’s not spicy!

  Sell

• TradeProtocol

  Dec 25, 2025

  $TEVA If this pharma company were a superhero, they'd definitely be the one saving lives while wearing a lab coat. Talk about a cape made of science!

  Buy

• PixelBroker

  Dec 24, 2025

  $TEVA They’re in the drug business, so think of them as the wizards of medicine. Just don’t ask them to conjure up a potion for your homework!

  Sell

• GainMachine

  Dec 24, 2025

  $TEVA Making pills faster than I make my bed—talk about productivity goals! 💊🌟

  Sell

• TheTradingVerse

  Dec 23, 2025

  $TEVA This company has been making strides in the pharmaceutical sector, focusing on innovative solutions that address critical healthcare needs. Its strong pipeline and commitment to reducing costs bolster its potential for long-term growth.

  Buy

• WallStreetGrim

  Dec 23, 2025

  $TEVA As a major player in pharmaceuticals, this company is continually adapting to regulatory challenges while focusing on providing accessible medications. Its extensive portfolio positions it to capture emerging market opportunities.

  Buy

• HedgeMeNot

  Dec 22, 2025

  $TEVA They’re in the health lane, but could hit some bumps!

  Sell

• QuantRift

  Dec 22, 2025

  $TEVA This organization, a leader in the pharmaceutical industry, is navigating a complex landscape while focusing on innovation and cost-effective solutions. Its robust pipeline and strategic partnerships may play a crucial role in driving future growth.

  Sell

• MarketWolf

  Dec 22, 2025

  $TEVA A storm brews in the pharmaceutical realm, and this stock is right in the thick of it! Outcomes are uncertain, leaving investors restless and anxious about the future.

  Buy

• OptionCipher

  Dec 21, 2025

  $TEVA With the pharmaceutical market shifting underfoot, this company is caught in a whirlwind of competition and regulatory challenges. Can they weather the storm and come out thriving? It’s a make-or-break moment!

  Sell

• TickerTrickster

  Dec 20, 2025

  $TEVA Pharma hustle on the grind, but feeling a lil shaky lately!

  Sell

• FiscalFury

  Dec 19, 2025

  $TEVA This company seems to be juggling pills like a circus performer. Just hope they don’t drop any – yikes!

  Sell

• CashCombo

  Dec 19, 2025

  $TEVA Making meds like a master chef—but instead of soufflés, it's all about keeping us feeling good! Bon appétit!

  Buy

• RiskRaider

  Dec 19, 2025

  $TEVA Still struggling to find its footing in a crowded market.

  Sell

• TheLongPlay

  Dec 19, 2025

  $TEVA Battling in the pharma ring, don’t count them out just yet.

  Sell

• CashMeOutside

  Dec 19, 2025

  $TEVA Big pharma flexin', but keep an eye on the drama!

  Sell

• MarketMarauder

  Dec 19, 2025

  $TEVA Pharmaceutical giant or just a giant disappointment?

  Sell

• VolatileViking

  Dec 18, 2025

  $TEVA This company is like a pharmacy that started a rock band—everyone wants its hits, but the lineup keeps changing!

  Buy

• DividendFrame

  Dec 17, 2025

  $TEVA With a diverse portfolio of products and a focus on generics, this pharmaceutical giant is strategically positioned to leverage market opportunities while navigating regulatory challenges.

  Buy

• ShortSniper

  Dec 17, 2025

  $TEVA Once a giant, now just a shadow of its former self.

  Sell

• CapitalCreep

  Dec 17, 2025

  $TEVA This pharma giant is more like a pharma toddler—lost and confused.

  Sell

• StonkZombie

  Dec 16, 2025

  $TEVA Big pharma's got some moves; don’t sleep on this one!

  Buy

• FiscalRiot

  Dec 15, 2025

  $TEVA With regulatory woes and patent expirations looming, this pharmaceutical giant is facing serious headwinds. Can they recover quickly, or are they headed for a steep decline?

  Sell

• OptionCipher

  Dec 15, 2025

  $TEVA Bullish tendencies strengthening.

  Buy

• WallStreetGrim

  Dec 15, 2025

  $TEVA Bearish retest rejection.

  Sell

• OptionCipher

  Dec 14, 2025

  $TEVA With constant fluctuations in the pharmaceutical landscape, this company is at a defining moment. The pressure to innovate and adapt is immense, will they rise to the occasion?

  Sell

• BagholderPrime

  Dec 14, 2025

  $TEVA Taking a pill for your portfolio? This stock may just be the cure for your financial woes—side effects may include happiness!

  Buy

• MarketMemeLord

  Dec 14, 2025

  $TEVA This player in the pharma game is ready to drop some serious healing magic!

  Buy

• CashOverload

  Dec 13, 2025

  $TEVA Bearish weight too strong.

  Sell

• CashClown

  Dec 13, 2025

  $TEVA This joint’s got mad potential, watch it rise like bread in the oven!

  Buy

• PortfolioPunk

  Dec 12, 2025

  $TEVA Struggling to keep up? Might as well hand over the reins.

  Sell

• CryptoCobra

  Dec 12, 2025

  $TEVA Like your favorite snack that always seems to be on sale—this company keeps popping up when you least expect it!

  Sell

• LazyQuant

  Dec 12, 2025

  $TEVA They’re taking the pharmaceutical game to new heights! Just don’t let your side effects include boredom.

  Buy

• DividendGhost

  Dec 11, 2025

  $TEVA In the pharmaceutical world, every day feels like a race against time for breakthroughs. Can this company overcome the mountains of generic competition, or will it falter under pressure?

  Sell

• CryptoCoyote

  Dec 11, 2025

  $TEVA With ongoing lawsuits and market volatility, the tension is palpable. Can this pharmaceutical player reclaim its footing, or will it fall deeper into the abyss?

  Sell

• ProfitLancer

  Dec 11, 2025

  $TEVA This pharmaceutical giant stumbles like a drunk at closing time.

  Sell

• BearishBoi

  Dec 11, 2025

  $TEVA With pharmaceuticals, it’s always a trip—let’s make sure it’s not one to the land of side effects!

  Sell

• MarketRender

  Dec 11, 2025

  $TEVA Major resistance holding firm.

  Sell

• YieldWarden

  Dec 10, 2025

  $TEVA This pharma heavyweight is under immense pressure to innovate amidst regulatory challenges. Their next moves could determine everything, and the stakes have never been higher!

  Sell

• ShortKingston

  Dec 9, 2025

  $TEVA Pharmaceuticals are like the magic potions of the stock world—may cause rapid heartbeats and oddly happy feelings!

  Buy

• TradeRebel

  Dec 9, 2025

  $TEVA This stock feels like it's stuck in quicksand! Legal battles and market pressures weigh heavily. Can they turn things around in time, or are they destined to sink further?

  Sell

• MarketMatrix

  Dec 9, 2025

  $TEVA Price unable to stabilize.

  Sell

• TheGainReaper

  Dec 9, 2025

  $TEVA What a shame to see such potential wasted.

  Sell

• StonkRider

  Dec 9, 2025

  $TEVA Market signaling deeper correction.

  Sell

• QuantRift

  Dec 9, 2025

  $TEVA Multi-day uptrend continuation expected.

  Buy

• AlphaDruid

  Dec 8, 2025

  $TEVA Amidst regulatory hurdles and competition, the tension in the air is thick! Will the upcoming trials bring clarity, or just more uncertainty? It's a nail-biter for sure.

  Sell

• ChartPilot

  Dec 8, 2025

  $TEVA With lawsuits looming and a challenging landscape, can this pharmaceutical giant regain its footing or is it destined for further decline?

  Sell

• CashOverload

  Dec 8, 2025

  $TEVA Pharmacology? More like a prescription for disappointment.

  Sell

• QuantRift

  Dec 8, 2025

  $TEVA This global pharmaceutical leader is focusing on expanding its generic drug portfolio and embracing biosimilars, which could enhance its competitive edge in a crowded market. Strategic innovations signal promising growth prospects.

  Buy

• ShortSavage

  Dec 8, 2025

  $TEVA The pharmaceutical landscape is so unpredictable right now! With patent cliffs looming, will they manage to innovate fast enough to stay ahead of the competition?

  Sell

• RiskProtocol

  Dec 7, 2025

  $TEVA This pharmaceutical giant is navigating a minefield of regulatory challenges and market competition. The urgency to deliver results is palpable, and one misstep could spell disaster.

  Sell

• CashCraze

  Dec 6, 2025

  $TEVA As a global leader in the pharmaceutical industry, this firm is navigating challenges while focusing on essential generic and specialty medications. Their strategic initiatives may pave the way for a strengthened market presence.

  Buy

• GammaSlayer

  Dec 6, 2025

  $TEVA Struggling under the weight of its own bad press.

  Sell

• TickerFlux

  Dec 5, 2025

  $TEVA This pharmaceutical giant is navigating a stormy sea of competition and litigation, making every quarter a nail-biter! Hold on tight as they attempt to steer through turbulent waters ahead.

  Sell

• FiscalRogue

  Dec 5, 2025

  $TEVA Chasing generics while the real competition leaves it in the dust.

  Sell

• BullishShade

  Dec 4, 2025

  $TEVA This pharmaceutical company continues to play a significant role in addressing global health challenges. Its innovative pipeline and commitment to biosimilars may lead to valuable breakthroughs with a positive market impact.

  Buy

• StonkViking

  Dec 4, 2025

  $TEVA Pharma's a wild ride, hold on tight for the ups and downs!

  Sell

• HoldTheLine

  Dec 4, 2025

  $TEVA This player’s been trippin', not sure if it's ready to bounce back.

  Sell

• MarketSavage

  Dec 4, 2025

  $TEVA Bullish reversal well underway.

  Buy

• TheRiskDealer

  Dec 4, 2025

  $TEVA Asset looks fundamentally weak.

  Sell

• CapitalCarnage

  Dec 4, 2025

  $TEVA Looks like a sinking ship with no lifeboats in sight.

  Sell

• ByteBull

  Dec 4, 2025

  $TEVA Pharmaceuticals: the ultimate ‘dad, I promise I’m studying!’ excuse. Just remember, the only side effects are your grades dropping!

  Buy

• PnLPhantom

  Dec 3, 2025

  $TEVA The pharmaceutical giant is caught in a whirlwind of litigation and market fluctuations. The stakes are high and the outcomes unpredictable, making every day a suspenseful ride for investors.

  Sell

• AlphaStriker

  Dec 3, 2025

  $TEVA This one’s like a headache – hard to shake off and costly.

  Sell

• BearHunter

  Dec 3, 2025

  $TEVA If medicine were a reality show, this company would be the dramatic comeback kid everyone roots for. Let’s see how they perform!

  Buy

• AlphaVandal

  Dec 2, 2025

  $TEVA Still trying to recover from its own disasters.

  Sell

• CapitalRush

  Dec 2, 2025

  $TEVA As a leading player in the pharmaceutical market, this company faces a competitive landscape but continues to evolve its portfolio. Its proactive approach to addressing healthcare needs is essential for maintaining relevance.

  Sell

• BullRunBoss

  Dec 2, 2025

  $TEVA These guys are like the caffeine in your morning coffee, keeping the world healthy and awake! Who knew pharmaceuticals could be this dynamic?

  Buy

• MarketWolf

  Dec 1, 2025

  $TEVA With constant changes in regulations and market dynamics, it's hard to predict how this pharmaceutical giant will navigate the storm of competition and innovation. Will they rise to the challenge or crumble under pressure?

  Sell

• TheMemeInvestor

  Nov 29, 2025

  $TEVA Pharma’s still in the kitchen cooking up some magic, feel me?

  Sell

• FOMOKing

  Nov 29, 2025

  $TEVA Old school pharmin' with a twist, keepin' it lit!

  Buy

• BullishSniper

  Nov 29, 2025

  $TEVA Like that reliable friend who always brings snacks to the party, you can count on this one!

  Buy

• SignalStriker

  Nov 29, 2025

  $TEVA With regulatory challenges looming and market dynamics shifting, this company is in a constant state of flux. It’s a gripping situation that demands close attention.

  Sell

• StonkSlayer

  Nov 28, 2025

  $TEVA Think of this as the superhero of pharmaceuticals—always saving the day, one pill at a time!

  Buy

• EquityEnigma

  Nov 28, 2025

  $TEVA With ongoing litigation and market pressures, this pharmaceutical giant is caught in a storm. Every decision carries weight, and the tension is palpable!

  Sell

• OptionCipher

  Nov 27, 2025

  $TEVA With uncertainties in the pharmaceutical realm and looming patent expirations, navigating this one feels like treading water during a storm. Keep your eyes peeled; volatility is the name of the game!

  Sell

• BearEater

  Nov 26, 2025

  $TEVA As a major player in the pharmaceutical industry, this company continues to leverage its extensive portfolio to address critical healthcare needs. Its potential for strategic growth remains strong despite market challenges.

  Buy

• MemeInvestor

  Nov 25, 2025

  $TEVA If this company were a pizza, it’d be topped with plenty of cheese and a side of pharmaceutical sauce! A recipe for success!

  Buy

• RiskRaider

  Nov 25, 2025

  $TEVA Overhyped pharma with underwhelming results.

  Sell

• PixelBroker

  Nov 24, 2025

  $TEVA This stock is like your favorite medicine—it might make you feel better during tough times. Just don’t forget to read the fine print on those side effects!

  Sell

• WallStreetBandit

  Nov 24, 2025

  $TEVA This pharma giant is stumbling more than a toddler learning to walk.

  Sell

• DividendHunter

  Nov 24, 2025

  $TEVA Just a shadow of its former self, drowning in debt.

  Sell

• YieldVector

  Nov 23, 2025

  $TEVA Amidst regulatory battles and market unpredictability, this pharma giant's future seems more uncertain than ever. The pressure is mounting, and the whispers of potential setbacks are hard to ignore.

  Sell

• HoldTheLine

  Nov 23, 2025

  $TEVA This pharma giant's been up and down, like a rollercoaster ride!

  Sell

• FiscalFrost

  Nov 22, 2025

  $TEVA A key player in the pharmaceutical market, this company is focused on developing and delivering high-quality generic medicines. Its expansive portfolio and commitment to innovation position it favorably against competitors in a dynamic healthcare landscape.

  Buy

• MemeInvestor

  Nov 22, 2025

  $TEVA If this stock were a painkiller, it would totally be the one that gives you a fast pass to feel awesome!

  Buy

• PortfolioFreak

  Nov 22, 2025

  $TEVA As regulatory hurdles loom, this pharmaceutical giant is caught in a storm, leaving investors anxious about its path forward!

  Sell

• MarketMarauder

  Nov 21, 2025

  $TEVA Treading water in a sea of lawsuits and controversy.

  Sell

• TradeNova

  Nov 21, 2025

  $TEVA Pharma heavyweight makin' moves, don’t sleep on this one!

  Buy

• BullishSniper

  Nov 20, 2025

  $TEVA When life gives you lemons, this company is the one handing you the aspirin—always ready to help out!

  Buy

• VolatileViking

  Nov 20, 2025

  $TEVA This company’s got more pills than a pharmacy on a Monday! Just don’t ask them for a prescription.

  Buy

• OptionCipher

  Nov 20, 2025

  $TEVA The pharmaceutical landscape is shifting rapidly, with patent cliffs looming. Every day feels like a ticking time bomb for this giant!

  Sell

• BearMarketSurvivor

  Nov 19, 2025

  $TEVA Big player in the game, just needs to regain the crown.

  Sell

• PixelBroker

  Nov 19, 2025

  $TEVA This company has more ups and downs than a rollercoaster! Buckle up for some wild rides in the pharma world!

  Buy

• TheRiskDealer

  Nov 19, 2025

  $TEVA Despite a portfolio that should be solid, looming legal issues and market pressures could sink them. Will they navigate these treacherous waters or find themselves in hot water?

  Sell

• MarketWolf

  Nov 19, 2025

  $TEVA With so much competition in pharmaceuticals, this giant is under serious pressure. Can they maintain their market share in such a cutthroat environment?

  Sell

• OptionNomad

  Nov 19, 2025

  $TEVA In the pharmaceutical race, this giant is under scrutiny. Can they resolve their legal troubles and innovate fast enough to reclaim their throne? The stakes couldn't be higher!

  Sell

• CodeAndCapital

  Nov 18, 2025

  $TEVA This one’s like that friend who always has the best snacks at the movies—never let it go out of stock!

  Buy

• EquityPulse

  Nov 17, 2025

  $TEVA Caught in the whirlwind of legal battles and market pressures, this pharmaceutical giant is walking a tightrope! Can they emerge unscathed, or will the pressure bring them down?

  Sell

• RiskDriver

  Nov 17, 2025

  $TEVA This company operates in the pharmaceutical sector, providing essential medications that address critical health needs. Their innovative approaches and strong pipeline could significantly impact their growth trajectory, especially as they navigate the evolving landscape of healthcare.

  Buy

• VolatilityNomad

  Nov 16, 2025

  $TEVA This one keeps tripping over its own feet.

  Sell

• GainVector

  Nov 15, 2025

  $TEVA Operating within the crucial pharmaceutical sector, this company is well-positioned to respond to evolving healthcare needs. Its extensive portfolio and strategic initiatives make it an interesting consideration for long-term stability.

  Sell

• OptionOutlaw

  Nov 15, 2025

  $TEVA Once a giant, now a sad echo of its former self.

  Sell

• StonkDestroyer

  Nov 15, 2025

  $TEVA This pharmaceutical could cure your financial headaches.

  Sell

• MarginLogic

  Nov 15, 2025

  $TEVA As a key player in pharmaceuticals, this company is navigating a landscape marked by challenges and opportunities. Its focus on research and development could pave the way for breakthroughs that capture market attention.

  Buy

• TradePredator

  Nov 14, 2025

  $TEVA A pharmaceutical giant still trying to find its way out of a legal maze.

  Sell

• MarketMatrix

  Nov 14, 2025

  $TEVA If pills could talk, this one would probably have the best gossip column in the pharmacy!

  Sell

• ProfitFang

  Nov 13, 2025

  $TEVA This company is well-positioned in the pharmaceutical sector, leveraging its extensive portfolio of generic and specialty medications. With a commitment to innovation and a strong pipeline, it continues to impact healthcare positively, making it a key player to watch.

  Buy

• StockSpecter

  Nov 12, 2025

  $TEVA Pharmaceuticals with this track record? Good luck!

  Sell

• LazyQuant

  Nov 11, 2025

  $TEVA If you think medicine is complicated, wait until you see the stock market. Just remember, pills help with headaches, but stocks can give you heartburn!

  Buy

• TheStockKnight

  Nov 11, 2025

  $TEVA Once a giant, now just a shadow of its former self.

  Sell

• FUDCrusher

  Nov 11, 2025

  $TEVA Got pills for days, but watch out for those market jitters, fam!

  Sell

• ChartPhantom

  Nov 11, 2025

  $TEVA This pharmaceutical stock is like your mom’s cure-all remedies—sometimes effective, sometimes just a spoonful of sugar!

  Buy

• WallStreetRogue

  Nov 11, 2025

  $TEVA Facing scrutiny and legal battles, the stakes are high! Is there light at the end of the tunnel, or are we heading into a storm?

  Sell

• DiamondHands

  Nov 10, 2025

  $TEVA This company is like the friend who always brings snacks to the hangout. Can't go wrong with a solid supply of good vibes and health!

  Buy

• StockSpecter

  Nov 10, 2025

  $TEVA Just another pharma giant with a reputation in free fall.

  Sell

• EquityPulse

  Nov 10, 2025

  $TEVA This stock is a battlefield! Every earnings report feels like a make-or-break moment, causing stress to skyrocket. Will it emerge victorious or succumb to the pressures?

  Buy

• MoneyMage

  Nov 10, 2025

  $TEVA This pharmaceutical giant is about as reliable as a leaky faucet.

  Sell

• CapitalCrusher

  Nov 10, 2025

  $TEVA This stock is like that one friend who's always got a remedy for your ailments—trustworthy and always ready to help!

  Buy

• BuyLowBro

  Nov 9, 2025

  $TEVA Making pills and saving lives, but still can’t help me with my allergies during allergy season!

  Buy

• FiscalBinary

  Nov 9, 2025

  $TEVA With patent cliffs looming ominously and competition intensifying, this company is at a crossroads. Can it navigate through the impending challenges unscathed?

  Sell

• BullRunBoss

  Nov 9, 2025

  $TEVA This pharmaceutical giant is trying to cure your woes. Spoiler alert: it’s not a magic potion, but it helps!

  Sell

• WallStreetBandit

  Nov 8, 2025

  $TEVA Struggling under the weight of its own mismanagement.

  Sell

• MarketMarauder

  Nov 8, 2025

  $TEVA Pharmaceutical giants falling apart? No surprise there.

  Sell

• BullishBard

  Nov 8, 2025

  $TEVA This one's like the medicine cabinet you wish you had—full of solutions for every little problem, including the one where you forgot your homework.

  Buy

• FiscalBinary

  Nov 8, 2025

  $TEVA With ongoing litigation and fluctuating demand, this pharmaceutical giant is like a rollercoaster ride—hold on tight and brace yourself for twists and turns in the market!

  Sell

• TendieTitan

  Nov 4, 2025

  $TEVA Candle after candle - this thing refuses to chill. Price action so smooth it deserves a.

  Buy

• HoldTheLine

  Nov 2, 2025

  $TEVA repair whispering chart eyes this

  Sell

• HODLWarrior

  Nov 1, 2025

  $TEVA fire deluxe dumpster

  Sell

• AlphaDecoder

  Oct 30, 2025

  $TEVA soon-ish buzzing wall tight tax choppy city whispers eyes bleeding frankly risk bear ouch mode mess

  Sell

• CandleFreak

  Oct 26, 2025

  $TEVA Momentum so steady it could teach yoga. Traders in disbelief, bulls in paradise.

  Sell

• GammaSlayer

  Oct 17, 2025

  $TEVA This volume deserves a standing ovation. Momentum so steady it.

  Sell

• TheFiscalShade

  Oct 12, 2025

  $TEVA supply sentiment hard fast city today heavy queued trap talking hard macro eyes mode money keeping bagholder levels no on

  Sell

• QuantQuest

  Oct 10, 2025

  $TEVA Technicals said no, emotions said yes - as usual. My.

  Buy

• CandleKnight

  Oct 9, 2025

  $TEVA Energy in this move is contagious - someone call CNBC.

  Buy

• YOLOTrader

  Oct 8, 2025

  $TEVA tape soon liquidity grind hands nimble clean wild smart candle levels soon-ish cat nasty heavy mode smart buzzing keeping nimble tape

  Sell

• AlphaDecoder

  Oct 6, 2025

  $TEVA This chart looks like it just had an energy drink.

  Sell

• OptionCipher

  Oct 1, 2025

  $TEVA charts vibes money clear no tape humming buzzing keeping money no smooth buzzing volume trigger hard dripping soon risk levels earnings today hurts trigger levels diamond

  Buy

• MarginMeme

  Sep 20, 2025

  $TEVA watching noise hard level-to-level mode hedges hands here trend eyes charts tape mode trend steady vol my nasty here my

  Sell

• MarginBeast

  Sep 19, 2025

  $TEVA deluxe dumpster fire

  Sell

• GammaSlayer

  Sep 16, 2025

  $TEVA Every breakout feels like a high-five from the trading gods. Energy.

  Sell

• QuantKnight

  Sep 9, 2025

  $TEVA diamond tape heavy steady king heater on patience passed trigger noise spike hedges trend gap tax no nimble grind grind

  Buy

• DiamondHandz

  Aug 19, 2025

  $TEVA bear aged confirmed cave like this residence milk

  Sell

• LiquidityLord

  Aug 19, 2025

  $TEVA If patience was a stock, I'd be rich by now.

  Buy

• MoneyMage

  Aug 15, 2025

  $TEVA Can't tell if it's consolidation or confusion. Bulls and bears are just trading insults.

  Sell

• TickerTrickster

  Aug 11, 2025

  $TEVA fire check pumping rocket money alpha tbh soon talking soon pumping heavy passed

  Buy

• EarningsEcho

  Jul 8, 2025

  $TEVA clean passed tight clean patience charts hard maybe dripping move heating nimble noise fast today

  Buy

• DiamondHands

  Jun 21, 2025

  $TEVA volume trend grind bull levels level-to-level grind hurts wild fire buzzing charts clean tape steady noise whoa

  Buy

• MarginMarauder

  Apr 21, 2025

  $TEVA maybe tight tape stops risk ruggy humming rough vol risk broken patience tight feels

  Sell

• YieldMyth

  Apr 2, 2025

  $TEVA rip clear earnings dive queued queued today fast hard nasty ugly sentiment energy keeping wild lower sentiment ruggy on

  Sell

• StonkZombie

  Jan 26, 2025

  $TEVA cliff hard flows money whoa out queued mode diamond tape flows rip trigger fast levels

  Sell

• TradeSaber

  Jan 24, 2025

  $TEVA trigger vibes charts wick steady diamond trap liquidity my noise

  Sell

• RiskVandal

  Dec 26, 2024

  $TEVA watching hard level-to-level look imo humming bagholder hurts wall cat soon sentiment energy buzzing here

  Sell

• EarningsSync

  Sep 11, 2024

  $TEVA now king earnings tight passed fast check tight pumping king alpha watching talking

  Buy

• DividendGhost

  Jul 29, 2024

  $TEVA on headfake tight ugly doom now feels liquidity imo here

  Sell

• RiskDriver

  Mar 30, 2024

  $TEVA maybe alpha feels theta dripping tape trigger today momentum tape imo pumping dripping gap grind money soon whoa

  Buy

• EquityAssault

  Mar 4, 2024

  $TEVA risk hedges session fading level-to-level risk clean rip it fast frankly money imo today mess

  Sell

• GainSurge

  Dec 28, 2023

  $TEVA buzzing spike candle candle levels no keeping tbh level-to-level wall smart lows soon heavy hard soon

  Sell